ICN DoJ settlement
Executive Summary
ICN Pharmaceuticals will plead guilty to one felony count for securities fraud in a plea agreement reached with the Los Angeles U.S. Attorney, as well as pay a $5.6 mil. fine and enter a three-year term of probation. DoJ charged that the company failed to disclose a 1994 "not approvable" letter for ribavirin monotherapy for hepatitis C and made false and misleading presentations that FDA's response was routine when the agency had "urged ICN to withdraw the application" (1"The Pink Sheet" Aug. 16, 1999, p. 11). The settlement also provides that the U.S. attorney will not prosecute ICN's officers; CEO Milan Panic was under investigation by the Securities & Exchange Commission...
You may also be interested in...
ICN's Failure To Disclose Ribavirin "Not Approvable" Letter Prompts SEC Suit
ICN Pharmaceuticals characterized FDA's November 1994 "not approvable" letter for ribavirin monotherapy as "typical regulatory correspondence" in communications with investors, the Securities and Exchange Commission charged in an Aug. 11 complaint filed in Los Angeles federal court.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.